To explore the effect of bivalirudin combined with alprostadil on myocardial blood perfusion, hematological parameters and prognosis in patients with acute ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
A total of 294 patients with acute STEMI admitted to our hospital from January 2021 to November 2024 were selected and divided into control group A (treated with bivalirudin), control group B (treated with heparin+alprostadil), and observation group (treated with bivalirudin+alprostadil) according to the random number table method, with 98 cases in each group. The thrombolysis in myocardial infarction test (TIMI) blood flow classification, corrected TIMI flow frame count (CTFC) after surgery, and the rate of no-reflow phenomenon were compared before and 10 minutes after the operation among the three groups. The levels of serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and hematological parameters in the three groups before and 3 days after the operation were compared. The occurrence of major adverse cardiac event (MACE) within 30 days after PCI in the three groups was statistically analyzed.
After the operation, the incidence of TIMI grade 3 in the observation group was higher than that in the control group (P<0.05), and the incidences of CTFC and the rate of no-reflow phenomenon were lower than those in the control group (P<0.05). Three days after the operation, the levels of serum IL-6, TNF-α, CRP, the ratio of neutrophil/lymphocyte, neutrophils, mean platelet volume, and the ratio of mean platelet volume/lymphocyte in the three groups were lower than those before the operation, while lymphocytes were higher than those before the operation (P<0.05), and (P<0.05). At 30 days after the operation, the incidence of MACE in the observation group was lower than that in the control group (P<0.05).
Bivalirudin combined with alprostadil can reduce the inflammatory response in patients with acute STEMI undergoing PCI, improve myocardial blood perfusion, and reduce the occurrence of postoperative MACE.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |